Exosome Research Market Size, Growth by Product and services (Kits, Reagents, Instrument), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem cell, Dendritic cell-derived), End User & Region - Global Forecast to 2026
The global exosome research market in terms of revenue was estimated to be worth $144 million in 2021 and is poised to reach $661 million by 2026, growing at a CAGR of 35.6% from 2021 to 2026. The growth of this market is driven by factors such as the rising funding for life sciences research, the high global prevalence of cancer, and the increasing interest in exosome-based procedures.
To know about the assumptions considered for the study, Request for Free Sample Report
Exosome Research Market Dynamics
Drivers: Increasing investments in pharmaceutical R&D and life science research
Most pharmaceutical, biopharmaceutical, and medical device companies invest heavily in developing novel drugs and devices. The pharmaceutical industry is R&D-intensive. Pharmaceutical companies invest in R&D to deliver high-quality and innovative products to the market. Trends suggest that the top pharma companies are increasing their R&D efficiencies through heavy R&D investments to see returns in the longer term and through collaborative R&D efforts. According to the EvaluatePharma report, worldwide pharmaceutical R&D spending was valued at USD 136 billion in 2012; this increased to USD 186 billion in 2019. As a result of the COVID-19 outbreak, the global pharma R&D growth rate dropped to 0.3% in 2020. As per the report, this R&D spend is expected to grow steadily between 2019 and 2026 at a CAGR of 3.2% to reach USD 232.5 billion, slower than the historical CAGR of 4.6% between 2012 and 2019.
Challenges: Lack of gold standard protocols for development & production of exosomes
The field of exosomes is still at a nascent stage, and no gold standards have been developed so far. Thus, professionals employ new procedures and methodologies introduced in the market without much hesitation. In addition to researchers making mistakes during exosome production, the scientists face several challenges in exosome research, development, and manufacturing. MSC-derived exosomes have gained significant interest recently as they can mediate as intercellular messengers. Their novel characteristic makes them attractive for biomedical applications such as vaccine development, cancer diagnosis, cell therapy, gene therapy, and drug delivery. Thus, MSC-exosome therapy developers need to tailor their stem cell-free therapy workflow under new exosome production requirements to develop effective exosome harvesting methods and set gold standards for exosome characterization and purification.
Opportunities: Rising demand for specialized testing services among end users
In recent years, partnering earlier in the drug development process as part of an effort to create efficiencies is a growing trend. Companies are increasingly outsourcing specialized testing services such as Liquid Chromatography-Mass Spectrometry (LC/MS), RNA sequencing, gene expression analysis, wet chemistry analysis of compendia raw materials, trace metal analysis with Inductively Coupled Mass Spectrometry (ICP-MS), and various others much earlier in the API process development cycle. These specialized services are mainly used for structural elucidation of key impurities, removing class I and II solvents, hazards analysis, removal of column chromatography, and efforts toward overall cost reduction and process efficiency.
By product and service, kits & reagents segment accounted for the largest share of the exosome research market in 2020.
Based on product and service, the global market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is further divided into antibodies, isolation, purification, quantitation kits & reagents, and other kits & reagents. Circulating exosomal microRNAs (miRNAs) have emerged as valuable biomarker candidates, making it imperative to characterize these exosomes carefully. This has propelled the use of these entities in exosome research to develop easy-to-use kits and reagents. Additionally, isolation and purification are critical steps in exosome research protocols, contributing to their large-scale adoption in the market.
By indication, the cancer accounted for the largest share of the exosome research market in 2020.
Based on indication, the global market is categorized into cancer, neurodegenerative diseases, cardiovascular diseases, infectious diseases, and other indications. The global market for cancer is segmented into lung cancer, prostate cancer, breast cancer, colorectal cancer, and other cancers. The large share of cancer segment is attributed to the high demand for exosome research products & services in lung cancer management.
By application, the biomarkers segment accounted for the largest share of the exosome research market in 2020.
Based on application, the exosome research products market is segmented into biomarkers, vaccine development, tissue regeneration, and other applications. The biomarkers segment generated the highest revenue in the global market in 2020. Exosomes can be isolated from easily attainable biofluids, including blood, urine, and saliva; this has supported their use as biomarkers in disease management. Exosomes are also being used in developing vaccines against the COVID-19 virus, which accounts for the high growth rate of the vaccine development segment.
By end user, the academic & research institutes segment accounted for the largest share of the exosome research market in 2020.
Based on end user, the global market is segmented into academic & research institutes, hospital & clinical testing laboratories, and pharmaceutical & biotechnology companies. There has been increasing demand for exosome research in the past few years due to their potential in disease diagnosis and their emerging role as intercellular messengers. This has piqued the interest of academic research professionals, contributing to the dominance of the academic & research institutes end-user segment in the market.
North America accounted for the largest share of the exosome research market in 2020.
Factors such as the availability of government funding for life sciences research, favorable regulatory environment, increasing focus on exosomes in research and diagnostics, and the presence of high-quality infrastructure for clinical and laboratory research are driving the growth of the exosomes market in North America.
To know about the assumptions considered for the study, download the pdf brochure
Thermo Fisher Scientific (US), Bio-Techne (US), Lonza (Switzerland), QIAGEN (Germany), Miltenyi Biotec (US), are the prominent players operating in the exosome research market.
Exosome Research Market Scope
|
Report Metric |
Details |
|
Market Size Available for Years |
2019–2026 |
|
Base Year Considered |
2020 |
|
Forecast Period |
2021–2026 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Product and Service, Indication, Application, End User, and Region. |
|
Geographies Covered |
North America, Europe, the Asia Pacific, and Rest of the World (RoW). |
|
Companies Covered |
The major market players include including Thermo Fisher Scientific (US), System Biosciences (US), Bio-Techne (US), Lonza (Switzerland), QIAGEN N.V. (Germany), NX PharmaGen (US), Miltenyi Biotec (US), AMS Biotechnology (US), NanoSomiX (US), Norgen Biotek Corp. (US), Novus Biologicals (US), BioVision Inc. (US), Pall Corporation (US), Exopharm Limited (Australia), and EverZom (France). |
The study categorizes the exosome research market into the following segments and subsegments:
By Product & Service
-
Kits & Reagents
- Antibodies
- Isolation, Purification, Quantitation Kits & Reagents
- Other Kits & Reagents
- Instruments
- Services
By Indication
-
Cancer
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Other Cancers
- Neurodegenerative Diseases
- Cardiovascular Diseases
- Infectious Diseases
- Other Indications
By Application
- Biomarkers
- Vaccine Development
- Tissue Regeneration
- Other Applications
By End User
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Hospital & Clinical Testing Laboratories
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Rest of Europe
-
Asia Pacific
- China
- Japan
- Rest of Asia Pacific
- RoW
Recent Developments
- In February 2022, Bio-Techne entered into an exclusive agreement with Thermo Fisher Scientific for the development and commercialization of the ExoTRU kidney transplant rejection test designed by Bio-Techne. This liquid biopsy test offers allograft health information suitable for both clinical and research applications.
- In November 2020, Lonza completed the acquisition of an exosome manufacturing facility of Codiak BioSciences. Through this development, the latter retained its pipeline of therapeutic candidates and exosome drug-loading technologies while receiving manufacturing services from Lonza.
- In September 2020, QIAGEN and Bio-Techne extended their non-exclusive partnership to co-market an exosome technology. Through this agreement, QIAGEN has been granted a non-exclusive development license to an exosome technology by Bio-Techne for the development of companion in vitro diagnostic products (CDX-IVD).
Frequently Asked Questions (FAQ):
What is the current size of the global exosome research market?
The global exosome research market is projected to reach USD 661 million by 2026 from USD 144 million in 2021, at a CAGR of 35.6% during the forecast period.
Who are the leading players in the exosome research market?
Some of the leading players in the exosome research products market include Thermo Fisher Scientific (US), Bio-Techne (US), Lonza (Switzerland), QIAGEN (Germany), Miltenyi Biotec (US).
What are the major applications of the exosome research market?
Based on application, the exosome research market is segmented into biomarkers, vaccine development, tissue regeneration, and other applications. The biomarkers segment accounted for the largest share of the exosome research market in 2020.
What are the major drivers of the exosome research market?
Some of the major drivers of the exosome research market includes The growth of this market is driven by factors such as the rising funding for life sciences research, the high global prevalence of cancer, and the increasing interest in exosome-based procedures. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 28)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 EXOSOME RESEARCH MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 32)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 EXOSOME RESEARCH MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF EXOSOME RESEARCH IN THE MARKET
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 GLOBAL MARKET: CAGR PROJECTIONS, 2021–2026
FIGURE 8 GLOBAL MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS CHALLENGES, AND OPPORTUNITIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.6.1 COVID-19 SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 43)
FIGURE 12 EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 13 GLOBAL MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 14 GLOBAL MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 15 GLOBAL MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT: GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 47)
4.1 EXOSOME RESEARCH MARKET OVERVIEW
FIGURE 17 RISING INVESTMENTS IN THE PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH
4.2 NORTH AMERICA: MARKET SHARE, BY PRODUCT & SERVICE AND COUNTRY (2020)
FIGURE 18 KITS & REAGENTS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2020
4.3 GLOBAL MARKET FOR CANCER, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 19 LUNG CANCER SEGMENT TO DOMINATE THE MARKET IN 2026
5 MARKET OVERVIEW (Page No. - 49)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 EXOSOME RESEARCH MARKET: DRIVERS, OPPORTUNITIES, RESTRAINTS, AND CHALLENGES
TABLE 1 GLOBAL MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Increasing investments in pharmaceutical R&D and life science research
5.2.1.2 Rising cancer prevalence
TABLE 2 GLOBAL CANCER INCIDENCE, 2020 VS. 2025
5.2.1.3 Increasing interest in exosome-based procedures
5.2.2 RESTRAINTS
5.2.2.1 Lack of skilled professionals
5.2.3 OPPORTUNITIES
5.2.3.1 Untapped emerging markets
5.2.3.2 Growing interest in exosome-based therapeutics
5.2.3.3 High demand for personalized medicine
5.2.4 CHALLENGE
5.2.4.1 Lack of gold standard protocols for development & production of exosomes
5.3 IMPACT OF COVID-19 OUTBREAK ON GLOBAL MARKET
TABLE 3 EXOSOME CONTRIBUTION IN COVID-19 CLINICAL RESEARCH
TABLE 4 ONGOING CLINICAL TRIALS FOR EXOSOME-BASED COVID-19 THERAPY
5.4 ECOSYSTEM AND VALUE CHAIN ANALYSIS
FIGURE 21 GLOBAL MARKET: ECOSYSTEM ANALYSIS
5.5 REGULATORY ANALYSIS
6 EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE (Page No. - 60)
6.1 INTRODUCTION
TABLE 5 GLOBAL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
6.2 KITS & REAGENTS
TABLE 6 EXOSOME RESEARCH KITS & REAGENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 7 NORTH AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 8 EUROPE: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 9 ASIA PACIFIC: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 10 EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
6.2.1 ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS
6.2.1.1 Rapid and easy-to-use kits and reagents have gained significant demand in the past few years in the market
TABLE 11 EXOSOME RESEARCH ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 12 NORTH AMERICA: EXOSOME RESEARCH ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 13 EUROPE: EXOSOME RESEARCH ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 14 ASIA PACIFIC: EXOSOME RESEARCH ISOLATION, PURIFICATION, AND QUANTITATION KITS & REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.2.2 ANTIBODIES
6.2.2.1 High demand for exosome-based markers for disease detection is expected to propel the segment growth
TABLE 15 EXOSOME RESEARCH ANTIBODIES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 16 NORTH AMERICA: EXOSOME RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 17 EUROPE: EXOSOME RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 18 ASIA PACIFIC: EXOSOME RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.2.3 OTHER KITS & REAGENTS
TABLE 19 OTHER EXOSOME RESEARCH KITS & REAGENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 20 NORTH AMERICA: OTHER EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 21 EUROPE: OTHER EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 22 ASIA PACIFIC: OTHER EXOSOME RESEARCH KITS & REAGENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 SERVICES
6.3.1 PLAYERS OFFER END-TO-END RESEARCH SERVICES FOR LABS
TABLE 23 EXOSOME RESEARCH SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 24 NORTH AMERICA: EXOSOME RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 25 EUROPE: EXOSOME RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 26 ASIA PACIFIC: EXOSOME RESEARCH SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.4 INSTRUMENTS
6.4.1 DEMAND FOR SCALABLE DEVELOPMENT OF EXOSOMES VIA HIGH THROUGHPUT SYSTEMS AUGMENTS THE SEGMENT GROWTH
TABLE 27 EXOSOME RESEARCH INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 28 NORTH AMERICA: EXOSOME RESEARCH INSTRUMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 29 EUROPE: EXOSOME RESEARCH INSTRUMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 30 ASIA PACIFIC: EXOSOME RESEARCH INSTRUMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 EXOSOME RESEARCH MARKET, BY INDICATION (Page No. - 73)
7.1 INTRODUCTION
TABLE 31 GLOBAL MARKET, BY INDICATION, 2019–2026 (USD MILLION)
7.2 CANCER
TABLE 32 GLOBAL MARKET FOR CANCER, BY REGION, 2019–2026 (USD MILLION)
TABLE 33 NORTH AMERICA: MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 34 EUROPE: MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 35 ASIA PACIFIC: MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 36 GLOBAL MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
7.2.1 LUNG CANCER
7.2.1.1 Increasing prevalence of lung cancer and technological advancements in instruments & assays for liquid biopsy to drive market growth
TABLE 37 GLOBAL MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
TABLE 38 NORTH AMERICA: MARKET FOR LUNG CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 39 EUROPE: MARKET FOR LUNG CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 40 ASIA PACIFIC: MARKET FOR LUNG CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
7.2.2 BREAST CANCER
7.2.2.1 High prevalence and increasing awareness to drive the market for this segment
TABLE 41 GLOBAL MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
TABLE 42 NORTH AMERICA: MARKET FOR BREAST CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 43 EUROPE: MARKET FOR BREAST CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 44 ASIA PACIFIC: MARKET FOR BREAST CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
7.2.3 PROSTATE CANCER
7.2.3.1 Liquid biopsy helps detect aggressive prostate cancer before surgery—a key factor driving market growth
TABLE 45 GLOBAL MARKET FOR PROSTATE CANCER, BY REGION, 2019–2026 (USD MILLION)
TABLE 46 NORTH AMERICA: MARKET FOR PROSTATE CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 47 EUROPE: MARKET FOR PROSTATE CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 48 ASIA PACIFIC: MARKET FOR PROSTATE CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
7.2.4 COLORECTAL CANCER
7.2.4.1 Increasing research activities and projects based on exosomes to drive the market for this segment
TABLE 49 GLOBAL MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2026 (USD MILLION)
TABLE 50 NORTH AMERICA: MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 51 EUROPE: MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 52 ASIA PACIFIC: MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
7.2.5 OTHER CANCERS
TABLE 53 GLOBAL MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 54 NORTH AMERICA: MARKET FOR OTHER CANCERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 55 EUROPE: MARKET FOR OTHER CANCERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 56 ASIA PACIFIC: MARKET FOR OTHER CANCERS, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 NEURODEGENERATIVE DISEASES
7.3.1 POTENTIAL OF SALIVARY EXOSOMAL CONTENT AS BIOMARKERS HAS OPENED AVENUES IN RESEARCH FOR NEURODEGENERATIVE DISEASES
TABLE 57 GLOBAL MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 58 NORTH AMERICA: MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 59 EUROPE: MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 60 ASIA PACIFIC: MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 CARDIOVASCULAR DISEASES
7.4.1 GROWING RESEARCH ON EXTRACELLULAR VESICLES FOR CVD TO PROPEL THE SEGMENT GROWTH
TABLE 61 GLOBAL MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 62 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 63 EUROPE: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 64 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 INFECTIOUS DISEASES
7.5.1 POTENTIAL USE OF EXOSOMES IN DEVELOPING NOVEL COVID-19 TREATMENT SOLUTIONS IS EXPECTED TO DRIVE THE MARKET
TABLE 65 GLOBAL MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 67 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 68 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
7.6 OTHER INDICATIONS
TABLE 69 GLOBAL MARKET FOR OTHER INDICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 70 NORTH AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 71 EUROPE: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 72 ASIA PACIFIC: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
8 EXOSOME RESEARCH MARKET, BY APPLICATION (Page No. - 92)
8.1 INTRODUCTION
TABLE 73 GLOBAL MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
8.2 BIOMARKERS
8.2.1 BIOMARKERS FORM THE LARGEST APPLICATION SEGMENT
TABLE 74 GLOBAL MARKET FOR BIOMARKERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 75 NORTH AMERICA: MARKET FOR BIOMARKERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 76 EUROPE: MARKET FOR BIOMARKERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 77 ASIA PACIFIC: MARKET FOR BIOMARKERS, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 VACCINE DEVELOPMENT
8.3.1 POTENTIAL OF EXOSOMES TO COMBAT BACTERIAL INFECTIONS DRIVING INTEREST IN VACCINE APPLICATIONS
TABLE 78 GLOBAL MARKET FOR VACCINE DEVELOPMENT, BY REGION, 2019–2026 (USD MILLION)
TABLE 79 NORTH AMERICA: MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 80 EUROPE: MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 81 ASIA PACIFIC: MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 TISSUE REGENERATION
8.4.1 STUDIES CONDUCTED ON MOLECULAR PAYLOADS OF EXOSOMES TO ENHANCE TISSUE REGENERATION DRIVES MARKET GROWTH
TABLE 82 GLOBAL MARKET FOR TISSUE REGENERATION, BY REGION, 2019–2026 (USD MILLION)
TABLE 83 NORTH AMERICA: MARKET FOR TISSUE REGENERATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 84 EUROPE: MARKET FOR TISSUE REGENERATION, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 85 ASIA PACIFIC: MARKET FOR TISSUE REGENERATION, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 OTHER APPLICATIONS
TABLE 86 GLOBAL MARKET FOR OTHER APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 87 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 88 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 89 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
9 EXOSOME RESEARCH MARKET, BY MANUFACTURING SERVICE (Page No. - 101)
9.1 INTRODUCTION
TABLE 90 GLOBAL MARKET, BY MANUFACTURING SERVICE, 2019–2026 (USD MILLION)
9.2 STEM CELL-DERIVED EXOSOME MANUFACTURING SERVICES
9.2.1 INCREASED DEMAND FOR MSC-EXOSOMES IN THERAPEUTICS AUGMENTS THE SEGMENT GROWTH
9.3 DENDRITIC CELL-DERIVED EXOSOME MANUFACTURING SERVICES
9.3.1 SIGNIFICANT DEVELOPMENTS IN DC-EXOSOME IMMUNOTHERAPY TO DRIVE MARKET GROWTH
9.4 OTHER MANUFACTURING SERVICES
10 EXOSOME RESEARCH MARKET, BY END USER (Page No. - 104)
10.1 INTRODUCTION
TABLE 91 GLOBAL MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2 ACADEMIC & RESEARCH INSTITUTES
10.2.1 ACADEMIC & RESEARCH INSTITUTES ARE THE LARGEST END USERS IN THE GLOBAL MARKET
TABLE 92 GLOBAL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
TABLE 93 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 94 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 95 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3.1 SIGNIFICANT DEVELOPMENTS IN NANOMEDICINE TO DRIVE MARKET GROWTH IN THIS END-USER SEGMENT
TABLE 96 EXOSOME RESEARCH MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 97 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 98 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 99 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
10.4 HOSPITAL & CLINICAL TESTING LABORATORIES
10.4.1 INCREASE IN ADOPTION OF EXOSOME-BASED ONCOLOGY RESEARCH SOLUTIONS TO DRIVE MARKET GROWTH IN THIS END-USER SEGMENT
TABLE 100 EXOSOME RESEARCH MARKET FOR HOSPITAL & CLINICAL TESTING LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 101 NORTH AMERICA: MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 102 EUROPE: MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 103 ASIA PACIFIC: MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
11 EXOSOME RESEARCH MARKET, BY REGION (Page No. - 111)
11.1 INTRODUCTION
TABLE 104 GLOBAL MARKET, BY REGION, 2019–2026 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 22 NORTH AMERICA: EXOSOME RESEARCH MARKET SNAPSHOT
TABLE 105 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 106 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 107 NORTH AMERICA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 108 NORTH AMERICA: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 109 NORTH AMERICA: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 110 NORTH AMERICA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 111 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.2.1 US
11.2.1.1 High burden of cancer and favorable public and private funding for research activities to drive market growth
FIGURE 23 US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES BY REGION/COUNTRY (2021)
TABLE 112 US: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 113 US: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 114 US: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 115 US: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 116 US: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 117 US: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Increasing funding for genome-based medical treatments to support market growth
TABLE 118 CANADA: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 119 CANADA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 120 CANADA: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 121 CANADA: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 122 CANADA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 123 CANADA: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3 EUROPE
FIGURE 24 EUROPE: EXOSOME RESEARCH MARKET SNAPSHOT
TABLE 124 EUROPE: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 125 EUROPE: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 126 EUROPE: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 127 EUROPE: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 128 EUROPE: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 129 EUROPE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 130 EUROPE: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Strong academic research base bolsters market growth
TABLE 131 GERMANY: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 132 GERMANY: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 133 GERMANY: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 134 GERMANY: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 135 GERMANY: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 136 GERMANY: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.2 UK
11.3.2.1 Growth in the life sciences industry to drive the market for exosome research in the UK
TABLE 137 UK: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 138 UK: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 139 UK: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 140 UK: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 141 UK: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 142 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Strong collaborative network between biotechnology entities and research institutes drives market growth
TABLE 143 FRANCE: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 144 FRANCE: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 145 FRANCE: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 146 FRANCE: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 147 FRANCE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 148 FRANCE: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.3.4 REST OF EUROPE
TABLE 149 ROE: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 150 ROE: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 151 ROE: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 152 ROE: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 153 ROE: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 154 ROE: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4 ASIA PACIFIC
TABLE 155 ASIA PACIFIC: EXOSOME RESEARCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 156 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 157 ASIA PACIFIC: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 158 ASIA PACIFIC: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 159 ASIA PACIFIC: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 160 ASIA PACIFIC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 161 ASIA PACIFIC: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Government initiatives to strengthen the biotechnology industry and the high prevalence of cancer are major factors driving market growth
TABLE 162 CHINA: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 163 CHINA: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 164 CHINA: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 165 CHINA: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 166 CHINA: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 167 CHINA: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 High prevalence of cancer and increasing healthcare expenditure are the key drivers for the exosome research market in the country
TABLE 168 JAPAN: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 169 JAPAN: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 170 JAPAN: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 171 JAPAN: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 172 JAPAN: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 173 JAPAN: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.4.3 REST OF ASIA PACIFIC
TABLE 174 ROAPAC: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 175 ROAPAC: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 176 ROAPAC: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 177 ROAPAC: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 178 ROAPAC: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 179 ROAPAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
11.5 REST OF THE WORLD
TABLE 180 ROW: EXOSOME RESEARCH MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 181 ROW: EXOSOME RESEARCH KITS & REAGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 182 ROW: MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 183 ROW: MARKET FOR CANCER, BY TYPE, 2019–2026 (USD MILLION)
TABLE 184 ROW: MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 185 ROW: MARKET, BY END USER, 2019–2026 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 147)
12.1 INTRODUCTION
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 25 EXOSOME RESEARCH MARKET: STRATEGIES ADOPTED
12.3 MARKET SHARE ANALYSIS
FIGURE 26 GLOBAL MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020)
12.4 COMPANY EVALUATION QUADRANT
12.4.1 STARS
12.4.2 EMERGING LEADERS
12.4.3 PERVASIVE PLAYERS
12.4.4 PARTICIPANTS
FIGURE 27 GLOBAL MARKET: COMPANY EVALUATION MATRIX, 2020 (TOP 10 PLAYERS)
12.5 COMPETITIVE BENCHMARKING
12.5.1 COMPANY SERVICE FOOTPRINT (10 COMPANIES)
FIGURE 28 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN GLOBAL MARKET
12.6 COMPETITIVE SCENARIO AND TRENDS
12.6.1 DEALS (2016–2019)
TABLE 186 GLOBAL MARKET: DEALS
12.6.2 PRODUCT LAUNCHES (2016–2019)
TABLE 187 GLOBAL MARKET: PRODUCT LAUNCHES
12.6.3 OTHER DEVELOPMENTS (2016–2019)
TABLE 188 GLOBAL MARKET: OTHER DEVELOPMENTS
13 COMPANY PROFILES (Page No. - 155)
13.1 KEY COMPANIES
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 189 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 29 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 190 THERMO FISHER SCIENTIFIC, INC.: PRODUCT OFFERINGS
TABLE 191 THERMO FISHER SCIENTIFIC, INC.: EXPANSIONS
13.1.2 SYSTEM BIOSCIENCES, LLC.
TABLE 192 SYSTEM BIOSCIENCES LLC: BUSINESS OVERVIEW
TABLE 193 SYSTEM BIOSCIENCES: PRODUCT & SERVICE OFFERINGS
TABLE 194 SYSTEM BIOSCIENCES LLC: DEALS
13.1.3 BIO-TECHNE
TABLE 195 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 30 BIO-TECHNE: COMPANY SNAPSHOT
TABLE 196 BIO-TECHNE: PRODUCT OFFERINGS
TABLE 197 BIO-TECHNE: PRODUCT LAUNCHES
TABLE 198 BIO-TECHNE: DEALS
13.1.4 QIAGEN
TABLE 199 QIAGEN: BUSINESS OVERVIEW
FIGURE 31 QIAGEN: COMPANY SNAPSHOT
TABLE 200 QIAGEN: PRODUCT OFFERINGS
TABLE 201 QIAGEN: DEALS
13.1.5 LONZA
TABLE 202 LONZA: BUSINESS OVERVIEW
FIGURE 32 LONZA: COMPANY SNAPSHOT
TABLE 203 LONZA: SERVICE OFFERINGS
TABLE 204 LONZA: DEALS
13.1.6 NX PHARMAGEN
TABLE 205 NX PHARMAGEN: BUSINESS OVERVIEW
TABLE 206 NX PHARMAGEN: SERVICE OFFERINGS
13.1.7 AMSBIO (AMS BIOTECHNOLOGY)
TABLE 207 AMSBIO: BUSINESS OVERVIEW
TABLE 208 AMSBIO: PRODUCT OFFERINGS
13.1.8 NANOSOMIX, INC.
TABLE 209 NANOSOMIX, INC.: BUSINESS OVERVIEW
TABLE 210 NANOSOMIX: PRODUCT OFFERINGS
13.1.9 MILTENYI BIOTEC
TABLE 211 MILTENYI BIOTEC: BUSINESS OVERVIEW
TABLE 212 MILTENYI BIOTEC: PRODUCT OFFERINGS
13.1.10 NORGEN BIOTEK CORP.
TABLE 213 NORGEN BIOTEK CORP.: BUSINESS OVERVIEW
TABLE 214 NORGEN BIOTEK: PRODUCT OFFERINGS
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 AETHLON MEDICAL, INC.
TABLE 215 AETHLON MEDICAL, INC.: COMPANY OVERVIEW
13.2.2 ANJARIUM BIOSCIENCES AG
TABLE 216 ANJARIUM BIOSCIENCES AG: COMPANY OVERVIEW
13.2.3 CILOA
TABLE 217 CILOA: COMPANY OVERVIEW
13.2.4 CLARA BIOTECH, INC.
TABLE 218 CLARA BIOTECH, INC.: COMPANY OVERVIEW
13.2.5 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
TABLE 219 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.: COMPANY OVERVIEW
13.2.6 ILIAS BIOLOGICS, INC.
TABLE 220 ILIAS BIOLOGICS, INC.: COMPANY OVERVIEW
13.2.7 NANOVIEW BIOSCIENCES
TABLE 221 NANOVIEW BIOSCIENCES: COMPANY OVERVIEW
13.2.8 RION, LLC
TABLE 222 RION, LLC: COMPANY OVERVIEW
13.2.9 CELL GUIDANCE SYSTEMS LLC
TABLE 223 CELL GUIDANCE SYSTEMS: COMPANY OVERVIEW
13.2.10 INOVIQ (BARD1 LIFE SCIENCES LTD.)
TABLE 224 INOVIQ: COMPANY OVERVIEW
13.2.11 NOVUS BIOLOGICALS
TABLE 225 NOVUS BIOLOGICALS: COMPANY OVERVIEW
13.2.12 BIOVISION INC.
TABLE 226 BIOVISION INC.: COMPANY OVERVIEW
13.2.13 PALL CORPORATION
TABLE 227 PALL CORPORATION: COMPANY OVERVIEW
13.2.14 EXOPHARM
TABLE 228 EXOPHARM: COMPANY OVERVIEW
13.2.15 EVERZOM
TABLE 229 EVERZOM: COMPANY OVERVIEW
14 APPENDIX (Page No. - 185)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORT
14.5 AUTHOR DETAILS
This technical, market-oriented, and financial study of the global exosome research market involved the extensive use of secondary sources, directories, and databases to identify and collect relevant information. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market growth prospects. The global size of the market (estimated through various research approaches) was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Data
The secondary sources referred to for this research study include publications from different sources, such as the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), International Society for Extracellular Vesicles (ISEV), and the UK Regenerative Medicine Platform (UKRMP). Secondary sources include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global market, which was validated through primary research.
Primary Data
After acquiring basic knowledge about the global market scenario, extensive primary research was conducted through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, from tier 1 and tier 2 companies engaged in offering services) across five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 40% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Primary research was used in this report to:
- Validate the market segmentation defined through a product and service portfolio assessment of the leading players in the exosome research market
- Understand key industry trends and issues defining the strategic growth objectives of market players
- Gather both demand- and supply-side validation of the key factors affecting the market growth (such as market drivers, challenges, and opportunities)
- Validate assumptions for the market sizing and forecasting model used for this study
- Understand the market position of leading players in the exosome research market and their market shares/rankings
To know about the assumptions considered for the study, download the pdf brochure
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Report Objectives
- To define, describe, and forecast the global exosome research market based on product and service, indication, application, end user, and region.
- To provide detailed information regarding the major factors influencing the market growth (drivers, opportunities, and industry-specific challenges) along with the current trends
- To strategically analyze micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
-
To forecast the revenue of market segments with respect to four major regions:
North America, Europe, the Asia Pacific, and Rest of the World (RoW) - To profile key players and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments in the global market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and research & development activities.
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the RoE market, by country
- Further breakdown of the RoAPAC exosome research products market, by country
- Breakdown of the LATAM & MEA markets, by country
Company Information
Detailed analysis and profiling of additional market players (up to 5) inclusive of:
- Business Overview
- Financial Information
- Product Offered
- Developments (Last three years)
Generating Response ...
Growth opportunities and latent adjacency in Exosome Research Market